Stocktoria
Axogen, Inc. AXGN
Nasdaq · stock · Electromedical & Electrotherapeutic Apparatus · website · IPO 1986-12-17
Axogen, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $225.2M | $187.3M | $159.0M | $138.6M | $127.4M | $112.3M | $106.7M | $83.9M | $60.4M | $41.1M |
| Gross profit | $167.4M | $142.0M | $121.9M | $108.8M | $104.4M | $90.7M | $89.4M | $71.0M | $51.1M | $34.6M |
| R&D expense | $32.9M | $27.8M | $27.3M | $25.6M | $24.2M | $17.8M | $17.5M | $11.8M | $6.7M | $4.2M |
| Operating income | -$7.8M | -$3.3M | -$21.5M | -$29.7M | -$25.4M | -$23.2M | -$31.4M | -$20.5M | -$8.0M | -$8.1M |
| Interest expense | — | — | $2.8M | $624,000 | $1.4M | $1.1M | $40,000 | $1.2M | $2.2M | $5.4M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$15.7M | -$10.0M | -$21.7M | -$28.9M | -$27.0M | -$23.8M | -$29.1M | -$22.4M | -$10.4M | -$14.4M |
| EPS (diluted) | $-0.34 | $-0.23 | $-0.51 | $-0.69 | $-0.65 | $-0.60 | $-0.74 | — | — | — |
| Operating cash flow | $812,000 | $4.5M | -$5.7M | -$16.1M | -$13.4M | -$9.6M | -$19.9M | -$17.9M | -$9.2M | -$11.2M |
| Free cash flow | -$2.9M | $1.4M | -$19.6M | -$36.1M | -$41.2M | -$31.5M | -$24.5M | -$24.1M | -$10.3M | -$12.2M |
| Cash & equivalents | $35.5M | $27.6M | $31.0M | $15.3M | $32.8M | $48.8M | $35.7M | $24.3M | $36.5M | $30.0M |
| Inventory | $42.4M | $33.2M | $23.0M | $18.9M | $16.7M | $12.5M | $13.9M | $12.0M | $7.3M | $5.5M |
| Total assets | $221.7M | $203.7M | $196.8M | $195.4M | $208.0M | $201.4M | $154.6M | $160.2M | $58.9M | $46.4M |
| Total liabilities | $92.8M | $99.8M | $101.2M | $94.4M | $95.5M | $78.2M | $22.5M | $13.2M | $33.7M | $31.4M |
| Shareholders' equity | $128.8M | $103.9M | $95.7M | $101.0M | $112.5M | $123.1M | $132.2M | $147.0M | $25.2M | $14.9M |
Growth · year-over-year · Revenue CAGR 20.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +20.2% | +17.8% | +14.7% | +8.8% | +13.4% | +5.2% | +27.1% | +38.9% | +47.0% | +50.4% |
| Free cash flow growth | -304.5% | — | — | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.